{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005101","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.586068+00:00","generated_at":"2026-06-12T03:16:32.362011+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celldex Q2 net loss $30.5M ($0.65/sh); Phase 2 CSU enrollment complete, topline by YE 2023","bullets":["Net loss of $30.5M ($0.65/sh) for Q2 2023 vs $36.0M ($0.77/sh) in Q2 2022; cash $252.7M.","Phase 2 CSU enrollment completed with 208 patients, 25% above target; topline data expected by YE 2023.","Phase 1b PN data planned for Q4 2023; Phase 2 EoE initiated, first patient dosed in July.","R&D expenses increased to $26.3M from $20.7M YoY, driven by barzolvolimab costs.","Cash runway sufficient through 2025 to fund planned Phase 2 studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005101","json":"https://secwatch.observer/filing/0001171843-23-005101.json","markdown":"https://secwatch.observer/filing/0001171843-23-005101.md","text":"https://secwatch.observer/filing/0001171843-23-005101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/0001171843-23-005101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/f8k_080823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:16:32.362011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84c1d850c1b08e81fd99c504c03b74df3ceb7187","claim":"Celldex Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Celldex Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/0001171843-23-005101-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}